Zur Rose Group
- Notice of an Extraordinary General Meeting to be held on 19 June 2017
- Setting the stage for raising additional funds to accelerate growth
As announced at the Annual General Meeting held on 4 May 2017, the Zur Rose Group is seeking to capitalise on the wide range of growth opportunities offered by the market to further expand its strong position in the European pharmaceutical mail-order sector. Against this background, the Board of Directors is evaluating options for raising additional funds. The options being considered by UBS and Berenberg on behalf of Zur Rose Group AG include an initial public offering with a capital increase ("IPO"), further private funding and also additional debt financing. To set the stage for an IPO, an Extraordinary General Meeting will be held on 19 June 2017. Shareholder approval of the business on the agenda would allow Zur Rose Group AG to proceed with an initial public offering, possibly even this year, if the circumstances are favourable.
At the Extraordinary General Meeting, the Board of Directors will propose the creation of authorised share capital representing 50 per cent of the existing share capital. In view of an initial public offering, the Board of Directors is proposing a revision and restatement of the Articles of Association to conform to the requirements for listed companies and, in particular, also to the provisions of the Ordinance Against Excessive Compensation in Listed Companies (Verordnung gegen übermässige Vergütungen bei börsenkotierten Aktiengesellschaften, VegüV). The revised and restated Articles of Association would only become effective on completion of an authorised increase in share capital in connection with an initial public offering by Zur Rose Group AG.
The Notice of the Extraordinary General Meeting and the full draft Articles of Association can be viewed at www.zurrosegroup.com | Investors & Media | General Meeting of Shareholders.
Lisa Lüthi, Head of Corporate Communications
Email: [email protected], telephone: +41 52 724 08 14
Zur Rose Group
Operating under the "Zur Rose" and "DocMorris" brands, the Swiss-based Zur Rose Group is Europe's leading online pharmacy and one of Switzerland's foremost wholesale suppliers to medical practitioners. Through its business model, it helps to ensure safe, reliable and high-quality pharmaceutical care, while also excelling in developing innovative medicines management services to increase the effectiveness of the medication process. This creation of added value, the strong focus on patients and the commitment to supply pharmaceuticals at low cost make the Group an important strategic partner for healthcare providers, payers and industry.
The Zur Rose Group is headquartered in Frauenfeld, from where it is also serves the Swiss market. In Germany and Austria, the Group operates through subsidiaries in Heerlen (Netherlands) and Halle an der Saale (Germany). Furthermore, it holds a majority interest in BlueCare in Winterthur, the leading provider of networking systems in the Swiss healthcare market. Employing more than 800 people at its various locations, the Zur Rose Group generated revenue of CHF 880 million in 2016.
Zur Rose Group AG's shares (Swiss security no. 4261528, ISIN CH0042615283) are traded on the Berner Kantonalbank's OTC-X, Zürcher Kantonalbank's eKMU-X and Lienhardt & Partners Private Bank Zurich Ltd's trading platforms. The CHF 50 million corporate bond issued in November 2012 for the purpose of financing the DocMorris acquisition is listed on the SIX Swiss Exchange (Swiss security no. 19972936, ISIN CH0199729366, ticker symbol ZRO12). zurrosegroup.com
This communication may contain statements about the future that use words such as, for example, "believe", "assume", "expect" and other similar expressions. Such statements about the future are subject to risks, uncertainties, and other factors, which can cause the true results of the company to differ significantly from that which is expressly or implicitly assumed in these statements. In view of these uncertainties, the reader should not depend on this type of statement about the future. The company gives no undertaking whatever to update such statements regarding the future, or to adapt them to future events or developments.